Antisense oligonucleotides for target validation in the CNS.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Current opinion in molecular therapeutics (Print)

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11713799
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of the Receptor Subtype Involved in the Analgesic Effect of Neurotensin

  1999cited by this paper
• Retention of heroin and morphine–6β–glucuronide analgesia in a new line of mice lacking exon 1 of MOR–1

  1999cited by this paper
• Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries

  1998cited by this paper
• Orphan opioid receptor antisense probes block orphanin FQ-induced hyperphagia.

  1998cited by this paper
• Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more.

  1998cited by this paper
• Orphanin FQ/nociceptin analgesia in the rat.

  1998cited by this paper
• The Spread and Uptake Pattern of Intracerebrally Administered Oligonucleotides in Nerve and Glial Cell Populations of the Rat Brain

  1998cited by this paper
• Intrastriatal and intraventricular injections of oligodeoxynucleotides in the rat brain: tissue penetration, intracellular distribution and c-fos antisense effects.

  1998cited by this paper
• Cloning and characterization of a mouse sigma1 receptor.

  1998cited by this paper
• Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo

  1998cited by this paper
• A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons.

  1998cited by this paper
• Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo

  1998cited by this paper
• Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS.

  1998cited by this paper
• The role of CRF2 receptors in corticotropin‐releasing factor‐and urocortin‐induced anorexia

  1998cited by this paper
• mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality.

  1998cited by this paper
• Central administration of Y5 receptor antisense decreases spontaneous food intake and attenuates feeding in response to exogenous neuropeptide Y.

  1998cited by this paper
• The influence of base sequence on the immunological properties of defined oligonucleotides.

  1998cited by this paper
• Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery.

  1997cited by this paper
• Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3'-alkylamino oligodeoxynucleotides, 2'-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids.

  1997cited by this paper
• Centrally administered oligodeoxynucleotides in rats: occurrence of non-specific effects.

  1997cited by this paper
• Inhibition of Food Intake by Neuropeptide Y Y5 Receptor Antisense Oligodeoxynucleotides

  1997cited by this paper
• Orphan anxiety.

  1997cited by this paper
• Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.

  1997cited by this paper
• Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior.

  1997cited by this paper
• Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids

  1997cited by this paper
• Pharmacokinetics of antisense analogues in the central nervous system.

  1997cited by this paper
• Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

  1996cited by this paper
• Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y

  1996cited by this paper
• Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

  1996cited by this paper
• Intracerebroventricular administration of missense oligodeoxynucleotide induces interleukin-6 mRNA expression in brain and spleen of rats.

  1996cited by this paper
• Appetite-Suppressing Effects of Urocortin, a CRF-Related Neuropeptide

  1996cited by this paper
• Antisense mapping the MOR‐1 opioid receptor: evidence for alternative splicing and a novel morphine‐6β‐glucuronide receptor

  1995cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper
• Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain.

  1995cited by this paper
• Phosphorothioate Oligodeoxynucleotides Bind to Basic Fibroblast Growth Factor, Inhibit Its Binding to Cell Surface Receptors, and Remove It from Low Affinity Binding Sites on Extracellular Matrix (*)

  1995cited by this paper
• Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.

  1995cited by this paper
• ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release.

  1995cited by this paper
• Pharmacokinetics of Antisense Oligonucleotides

  1995cited by this paper
• Vasopressin Antisense Oligonucleotide Induces Temporary Diabetes Insipidus in Rats

  1994cited by this paper
• Stability of peptide nucleic acids in human serum and cellular extracts.

  1994cited by this paper
• Intracerebroventricular Administration of AT1 Receptor Antisense Oligonucleotides Inhibits the Behavioral Actions of Angiotensin II

  1994cited by this paper
• Convection-enhanced delivery of macromolecules in the brain.

  1994cited by this paper
• Dopamine receptor pharmacology.

  1994cited by this paper
• Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion.

  1994cited by this paper
• Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding.

  1994cited by this paper
• Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides.

  1993cited by this paper
• PNA hybridizes to complementary oligonucleotides obeying the Watson–Crick hydrogen-bonding rules

  1993cited by this paper
• Angiotensin II receptor antagonists and receptor subtypes.

  1992cited by this paper

• Overview of nanogel and its applications

  2021cites this paper
• Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

  2016cites this paper
• Genomic Analysis of wig-1 Pathways

  2012cites this paper
• Post-traumatic anxiety associates with failure of the innate immune receptor TLR9 to evade the pro-inflammatory NFκB pathway

  2012cites this paper
• Antisense Oligonucleotides and RNA Interference

  2011cites this paper
• siRNAs in drug discovery: target validation and beyond.

  2007cites this paper
• Improved targeting of miRNA with antisense oligonucleotides

  2006cites this paper
• Progress towards in Vivo Use of siRNAs

  2006cites this paper
• Oligonucleotide therapeutics: 25 years agrowing.

  2004cites this paper
• Nanogels for oligonucleotide delivery to the brain.

  2004cites this paper
• Homer1 proteins and AMPA receptors modulate cocaine‐induced behavioural plasticity

  2003cites this paper
• Reducing GABA receptors.

  2003cites this paper